Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRXNASDAQ:CRNXNASDAQ:CRONNASDAQ:HCM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$23.22-1.9%$23.91$14.75▼$26.58$2.87B0.721.13 million shs1.12 million shsCRNXCrinetics Pharmaceuticals$30.85-1.1%$31.29$24.10▼$62.53$2.97B0.28845,717 shs539,130 shsCRONCronos Group$1.91-1.0%$1.91$1.60▼$2.54$744.37M1.041.34 million shs802,984 shsHCMHUTCHMED$15.71-6.4%$14.51$11.51▼$21.50$2.95B0.5299,951 shs65,418 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals+0.59%-8.40%-2.87%+7.20%+57.17%CRNXCrinetics Pharmaceuticals-1.79%-3.35%-0.13%-8.72%-31.17%CRONCronos Group0.00%-1.53%-9.81%+4.32%-18.91%HCMHUTCHMED-0.65%+5.20%+25.39%+12.31%-7.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPRXCatalyst Pharmaceuticals4.7735 of 5 stars3.62.00.03.93.23.32.5CRNXCrinetics Pharmaceuticals3.3785 of 5 stars3.50.00.03.72.12.50.0CRONCronos Group1.761 of 5 stars0.05.00.00.03.60.01.3HCMHUTCHMED1.3131 of 5 stars2.02.00.00.02.10.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 3.25Buy$32.8341.40% UpsideCRNXCrinetics Pharmaceuticals 2.91Moderate Buy$74.56141.67% UpsideCRONCronos Group 0.00N/AN/AN/AHCMHUTCHMED 2.00Hold$19.0020.94% UpsideCurrent Analyst Ratings BreakdownLatest CRON, HCM, CRNX, and CPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025HCMHUTCHMEDHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold3/25/2025CRNXCrinetics PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.00(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$491.73M5.76$2.41 per share9.62$6.10 per share3.81CRNXCrinetics Pharmaceuticals$1.04M2,777.39N/AN/A$14.29 per share2.16CRONCronos Group$117.61M6.26$0.00 per share4,147.68$2.90 per share0.66HCMHUTCHMED$630.20M4.35$0.27 per share58.84$4.43 per share3.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$163.89M$1.5714.7910.900.9636.91%42.45%36.59%8/6/2025 (Estimated)CRNXCrinetics Pharmaceuticals-$298.41M-$3.82N/AN/AN/AN/A-30.95%-28.12%8/6/2025 (Estimated)CRONCronos Group$41.08M$0.1314.6963.6743.7639.69%-0.07%-0.07%8/6/2025 (Estimated)HCMHUTCHMED$37.73MN/A0.0010.76N/AN/AN/AN/A6/18/2025 (Estimated)Latest CRON, HCM, CRNX, and CPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CRNXCrinetics Pharmaceuticals-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 million5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/ACRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A5.114.92CRNXCrinetics PharmaceuticalsN/A16.3916.38CRONCronos GroupN/A24.2423.05HCMHUTCHMED0.072.812.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%CRNXCrinetics Pharmaceuticals98.51%CRONCronos Group8.71%HCMHUTCHMED8.82%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%CRNXCrinetics Pharmaceuticals6.00%CRONCronos Group6.90%HCMHUTCHMED3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80121.97 million109.29 millionOptionableCRNXCrinetics Pharmaceuticals21093.63 million88.01 millionOptionableCRONCronos Group450385.68 million359.07 millionOptionableHCMHUTCHMED1,811174.32 million168.05 millionNot OptionableCRON, HCM, CRNX, and CPRX HeadlinesRecent News About These CompaniesHUTCHMED (NASDAQ:HCM) Shares Gap Down - Time to Sell?June 17 at 12:43 PM | marketbeat.comHUTCHMED (NASDAQ:HCM) Lowered to Buy Rating by Wall Street ZenJune 15 at 3:43 AM | americanbankingnews.comHUTCHMED (NASDAQ:HCM) Downgraded to "Buy" Rating by Wall Street ZenJune 14 at 1:57 AM | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Up - Time to Buy?June 12, 2025 | marketbeat.comHutchmed introduces new share options and LTIP awardsJune 11, 2025 | uk.investing.comHUTCHMED Grants Share Options and LTIP Awards to Boost Talent RetentionJune 10, 2025 | tipranks.comHUTCHMED (NASDAQ:HCM) Rating Increased to Strong-Buy at Wall Street ZenJune 9, 2025 | americanbankingnews.comHUTCHMED (NASDAQ:HCM) Upgraded by Wall Street Zen to "Strong-Buy" RatingJune 7, 2025 | marketbeat.comWall Street Analysts See a 68.3% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?June 5, 2025 | zacks.comChina accepts NDA for sintilimab and fruquintinib combo in kidney cancerJune 5, 2025 | msn.comInnovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell CarcinomaJune 4, 2025 | prnewswire.comHUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell CarcinomaJune 4, 2025 | globenewswire.comHUTCHMED (NASDAQ:HCM) Shares Gap Up - Still a Buy?June 3, 2025 | marketbeat.comHUTCHMED’s SACHI Phase III Study Shows Promising Results for Lung Cancer TreatmentJune 1, 2025 | tipranks.comHUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual MeetingJune 1, 2025 | globenewswire.comMillennium Management LLC Sells 100,366 Shares of HUTCHMED (China) Limited (NASDAQ:HCM)June 1, 2025 | marketbeat.comTrinity Delta Estimates HUTCHMED FY2025 EarningsMay 31, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Trims Position in HUTCHMED (China) Limited (NASDAQ:HCM)May 27, 2025 | marketbeat.comBNP Paribas Financial Markets Trims Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM)May 26, 2025 | marketbeat.comHUTCHMED to Present Promising Oncology Data at 2025 ASCO MeetingMay 22, 2025 | tipranks.comHUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual MeetingMay 22, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsMicron Joins Latest $200 Billion United States Investment By Gabriel Osorio-Mazilli | June 16, 2025View Micron Joins Latest $200 Billion United States Investment CRON, HCM, CRNX, and CPRX Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$23.22 -0.45 (-1.90%) Closing price 04:00 PM EasternExtended Trading$23.33 +0.11 (+0.47%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Crinetics Pharmaceuticals NASDAQ:CRNX$30.85 -0.35 (-1.12%) Closing price 04:00 PM EasternExtended Trading$30.84 -0.01 (-0.03%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Cronos Group NASDAQ:CRON$1.91 -0.02 (-1.04%) Closing price 04:00 PM EasternExtended Trading$1.91 0.00 (0.00%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.HUTCHMED NASDAQ:HCM$15.71 -1.08 (-6.43%) Closing price 04:00 PM EasternExtended Trading$15.68 -0.03 (-0.18%) As of 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Downgrades Joby, But Overlooks Major Regulatory Wins Applied Digital: Now the High-Stakes Race to Build Begins Zscaler Upgraded: Wall Street Forecasts 26% More Upside U.S. Steel Stock Burns the Bears With Surprise Upside Move Is CrowdStrike Stock Set to Break Out or Cool Off? New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 The Bottom Is in for Powerfleet: An Intelligent Time to Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
